Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NUMA.0000719412.67108.17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review.
Rheumatol Int
January 2025
Division of Hematology-Oncology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of various hematological malignancies. Recently, CAR-T has been used in refractory auto-immune diseases with initial encouraging results. In this systematic review, we examined the safety and efficacy of CAR-T in patients with refractory auto-immune diseases.
View Article and Find Full Text PDFCAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.
Front Immunol
January 2025
Innovation & Research Department, OriCell Therapeutics Co. Ltd., Shanghai, China.
Article Synopsis
- Systemic lupus erythematosus (SLE) and lupus nephritis (LN) are autoimmune disorders that lead to chronic inflammation and organ damage, with current treatments lacking a definitive cure.
- Recent studies suggest that chimeric antigen receptor T-cell (CAR-T) therapy, which has been effective in B-cell cancers, may also be a breakthrough treatment for SLE.
- This paper analyzes CAR-T therapy's mechanisms, clinical data on its efficacy in targeting B-cells for SLE treatment, and emphasizes the need for further research in improving therapeutic strategies for these complex conditions.
Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.
BioDrugs
December 2024
Department of Allergy and Clinical Immunology, St James' University Hospital, Leeds, UK.
B-cell depleting therapy (BCDT) has revolutionised the treatment of B-cell malignancies and autoimmune diseases by targeting specific B-cell surface antigens, receptors, ligands, and signalling pathways. This narrative review explores the mechanisms, applications, and complications of BCDT, focusing on the therapeutic advancements since the introduction of rituximab in 1997. Various monoclonal antibodies and kinase inhibitors are examined for their roles in depleting B cells through antibody-dependent and independent mechanisms.
View Article and Find Full Text PDFNeurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data.
Transplant Cell Ther
December 2024
Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Chimeric antigen receptor T (CAR T) cell therapies have emerged as a valuable treatment modality for patients with plasma cell disorders. As the population of patients receiving CAR T therapies grows, the identification and management of associated rare toxicities become increasingly crucial. This study aims to identify safety signals associated with commercial anti-B-cell maturation antigen (BCMA) CAR T therapies using the Food and Drug Administration Adverse Event Reporting System (FAERS).
View Article and Find Full Text PDFClinical updates of B‑cell maturation antigen‑targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review).
Int J Mol Med
February 2025
Department of Gastrointestinal Surgery, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421002, P.R. China.
Despite significant progress in managing multiple myeloma (MM) in recent years, certain patients still have a short duration of therapeutic response, often relapsing within 18 months. These patients typically have high‑risk genetic mutations and may show little to no response to current treatments, highlighting the need for further exploration of optimal therapeutic targets for MM. B‑cell maturation antigen (BCMA), highly expressed in mature B lymphocytes and plasma cells and upregulated in MM, is a promising therapeutic target.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!